Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Microbot Medical, Inc. (NASDAQ: MBOT) is a pioneering pre-clinical medical device company focused on developing groundbreaking micro-robotic medical technologies. Established with the vision to transform minimally invasive surgeries—a fast-growing sector estimated to be close to $20 billion by 2015—Microbot Medical aims to provide cutting-edge micro-invasive technologies that assist physicians in targeting disease sites with unmatched precision. The company's innovative platforms, such as LIBERTY and the Self-Cleaning Shunt (SCS), are designed to improve surgical outcomes and the quality of life for millions of patients globally.
One of Microbot Medical's core technologies, the Virob platform, is an autonomous advancing micro-robot (AAMR) less than 1mm in diameter. This micro-robot can advance forward and backward autonomously, providing precise navigation through the body. Similarly, the LIBERTY Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by eliminating the need for bulky and expensive equipment while reducing radiation exposure and physician strain.
Microbot Medical has been achieving significant milestones, including positive results from its pivotal GLP pre-clinical study and its recent Investigational Device Exemption (IDE) application to the FDA. These advancements pave the way for the company's first human clinical trials. Furthermore, the company has secured both domestic and global patents, fortifying its product portfolio and creating significant barriers to entry for competitors.
Microbot Medical is actively engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for the LIBERTY system once it receives regulatory approval. The company is committed to advancing its technologies and aims to integrate future capabilities such as remote operations, imaging integration, and AI functionalities.
Despite challenges such as the COVID-19 pandemic and recent geopolitical events in Israel, Microbot Medical continues to meet its planned timelines and milestones. The company’s operations in Israel, the USA, and other parts of the globe remain uninterrupted, and it believes it will achieve regulatory and commercial milestones as scheduled.
For further information about Microbot Medical, please visit www.microbotmedical.com.
Microbot Medical Inc. (Nasdaq: MBOT) has been notified by the Japan Patent Office (JPO) that it intends to grant a patent for its innovative ‘One & Done’ guidewire technology aimed at endoluminal interventions. This marks Japan as the second jurisdiction to recognize this patent, enhancing the company’s intellectual property protection. CEO Harel Gadot highlighted the positive feedback from the medical community regarding their LIBERTY™ Robotic system and noted that the allowed claims cover a dual guidewire structure with adjustable states. Currently, Microbot holds 41 issued patents and has 22 pending applications.
Microbot Medical Inc. (Nasdaq: MBOT) announced successful discussions with the FDA regarding its Self-Cleaning Shunt (SCS). The FDA's feedback allows the company to apply for an Early Feasibility Study (EFS), paving the way for a First-in-Human (FIH) clinical trial projected for Q3 2022. CEO Harel Gadot highlighted this as a significant milestone, noting confidence in the strength of their pre-clinical data. This innovative device aims to prevent obstruction in cerebrospinal fluid catheters for patients with hydrocephalus.
Microbot Medical (Nasdaq: MBOT) has expanded its Scientific Advisory Board (SAB) with five renowned medical experts to enhance its leadership in micro-robotic technologies. The newly appointed members include specialists in interventional radiology and stroke therapy, such as Stephen B. Solomon, MD, and Ajay K. Wakhloo, MD PhD FAHA. CEO Harel Gadot emphasized the importance of attracting top talent to achieve significant clinical and regulatory milestones. Microbot Medical focuses on developing transformative technologies for minimally invasive procedures, contributing to advancements in the healthcare sector.
Microbot Medical (Nasdaq: MBOT) successfully completed an additional feasibility animal study of its LIBERTY™ Robotic System, achieving key study endpoints without any intraoperative adverse events. This study confirms LIBERTY's potential to enhance the safety and ease of conducting catheter-based neurovascular procedures remotely, minimizing risks associated with radiation exposure and contamination. CEO Harel Gadot expressed confidence in the system's performance and usability in clinical settings, with plans for further studies in the upcoming year to meet regulatory objectives.
Microbot Medical (Nasdaq: MBOT) has reported significant achievements for 2020, including the launch of the LIBERTY™ Robotic System, the first fully disposable surgical robotic system. Animal feasibility studies showed no adverse events, supporting remote catheter procedures to minimize physician risk. The company expanded its intellectual property with 40 patents granted. Leadership strengthened with new CMO and Board members, enhancing strategic capability. Looking ahead, Microbot aims to finalize FDA submissions for its technologies and continue exploring M&A opportunities in 2021.
Microbot Medical Inc. (Nasdaq: MBOT) announced that CEO Harel Gadot will present virtually at two investor conferences in January 2021. During the HCW Wainwright Bioconnect Conference, Mr. Gadot will engage in a fireside chat, with a video available on-demand from January 11-14. Additionally, he will present at the Needham Growth Conference on January 14 at 2:00 PM. Both presentations will be accessible via the Company’s website under the 'Investors' section. Microbot Medical focuses on micro-robotic technologies aimed at improving clinical outcomes for patients.
Microbot Medical (Nasdaq: MBOT) has announced the issuance of multiple patents, reinforcing its Intellectual Property (IP) portfolio, now comprising 40 issued/allowed patents and 23 pending applications globally. The USPTO granted a Notice of Allowance for its Self-Cleaning Shunt, enhancing its medical device technologies. Additionally, a European patent was granted for its guidewire technology under the LIBERTY development. CEO Harel Gadot emphasized the importance of a strong IP strategy to drive product development and future commercial opportunities.
Microbot Medical (Nasdaq: MBOT) will present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 2:00 PM ET. CEO Harel Gadot will discuss the company's recent progress and achievements. The event will also provide opportunities for virtual one-on-one meetings with executives for institutional investors. Gadot emphasizes the company's commitment to advancing its micro-robotic technologies toward commercialization. A live webcast will be available on the company's website for those interested.
Microbot Medical (Nasdaq: MBOT) received a Notice of Allowance for patent application No. 15/592,227 from the USPTO, enhancing its IP portfolio in devices for reducing dialysis shunt stenosis. This continuation of an existing patent reflects the company's commitment to protecting its innovative technologies. The newly allowed patent covers a system that reduces venous stenosis during hemodialysis, utilizing a novel clearing device. With a total of 39 issued/allowed patents and 23 pending applications globally, Microbot aims to solidify its competitive advantage in micro-robotic technologies.
Microbot Medical Inc. (NASDAQ: MBOT) will host a webinar on August 26, 2020, at 11:00 AM ET, following a successful presentation at the Needham Virtual Med Tech & Diagnostic Conference. CEO Harel Gadot will discuss the LIBERTYTM Robotic System, which has achieved all endpoints in a recent feasibility animal study with no adverse events. The system's capabilities may enable catheter-based procedures to be performed remotely, enhancing clinical outcomes while minimizing risks like radiation exposure. Management will also address audience questions during the session.
FAQ
What is the current stock price of Microbot Medical (MBOT)?
What is the market cap of Microbot Medical (MBOT)?
What is Microbot Medical, Inc.?
What is the LIBERTY Endovascular Robotic Surgical System?
What recent achievements has Microbot Medical accomplished?
What are the core technologies developed by Microbot Medical?
What is the vision of Microbot Medical?
How is Microbot Medical preparing for commercialization?
What impact do recent geopolitical events have on Microbot Medical's operations?
What is the Self-Cleaning Shunt (SCS) developed by Microbot Medical?
Who is acting as the exclusive placement agent for Microbot Medical's offering?
How can I get more information about Microbot Medical?
